Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

Finasteride may help treat Pseudomonas aeruginosa infections by reducing its harmful activities.

Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.

PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

SDG helps reduce BPH effects in rats.

5α-reductase affects dopamine receptors linked to sensorimotor gating, which may help understand disorders like schizophrenia.

Progesterone reduces spinal reflex activity by increasing certain GABA(A) receptor subtypes.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Daprodustat, combined with PAβN, could be a new antibacterial treatment.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

GMG-43AC may help reduce unwanted hair growth and treat certain hair loss conditions.

Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.

Finasteride helps improve treatment for benign prostatic hyperplasia.

These medications for BPH have known risks and may have new side effects.

Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.

Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.